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The biosynthesis and metabolism of cholesterol in the brain is spatiotemporally and developmentally regulated. Brain cholesterol
plays an important role in maintaining the function of neuronal receptors, which are key components in neural signal transduction. This
is illustrated by the requirement of membrane cholesterol for the function of the serotonin1A receptor, a transmembrane neurotransmitter
receptor. A crucial determinant for the function of neuronal receptors could be the availability of brain cholesterol. The Smith–Lemli–
Optiz Syndrome, a metabolic disorder characterized by severe neurodegeneration leading to mental retardation, represents a condition in
which the availability of brain cholesterol is limited. A comprehensive molecular analysis of lipid–protein interactions in healthy and
diseased states could be crucial for a better understanding of the pathogenesis of psychiatric disorders.
 2007 Elsevier Inc. All rights reserved.
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high concentration of lipids, and displays remarkable lipid
diversity [1]. The lipid composition of cells that make up
the nervous system is unique and has been correlated with
increased complexity in the organization of the nervous
system during evolution [2]. Organization and dynamics
of cellular membranes in the nervous system play a crucial
role in the function of neuronal membrane receptors. Cho-
lesterol is an important lipid in this context since it is
known to regulate the function of membrane receptors
[3], especially neuronal receptors [4], thereby affecting neu-
rotransmission and possibly giving rise to mood and anxi-
ety disorders [5]. Cholesterol is a predominantly
hydrophobic molecule comprising a near planar tetracy-
clic-fused steroid ring and a flexible isooctyl hydrocarbon
tail (see Fig. 1a). The 3b-hydroxyl moiety provides choles-
terol its amphiphilic character causing to orient in0006-291X/$ - see front matter  2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2007.01.032
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E-mail address: amit@ccmb.res.in (A. Chattopadhyay).membrane bilayer with its long axis perpendicular to the
plane of the membrane (see Fig. 1b). Interestingly, it has
been reported that tail-to-tail cholesterol dimers spanning
the two leaflets of the membrane bilayer can be formed
under certain conditions [6–11].
Cholesterol is an abundant and essential component of
eukaryotic membranes and plays a crucial role in mem-
brane organization, dynamics, function, and sorting
[12,13]. Cholesterol is often found distributed nonrandom-
ly in domains or pools in biological and model membranes
[10,12–16]. Many of these domains (sometimes termed as
‘lipid rafts’) are believed to be important for the mainte-
nance of membrane structure and function. The idea of
such specialized membrane domains assumes significance
in cell biology since physiologically important functions
such as membrane sorting and trafficking [17] and signal
transduction processes [18], in addition to the entry of
pathogens [19,20], have been attributed to these domains.
Interestingly, a strong asymmetry exists even in the
manner cholesterol is distributed among various organs
in the body of higher eukaryotes. For example, the central
nervous system, which accounts for only 2% of the body
mass contains 25% of free cholesterol present in the
whole body [21]. Although the brain is highly enriched in
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Fig. 1. Chemical structure and membrane orientation of cholesterol. Three structurally distinct regions are shown as shaded boxes in (a): the 3b-hydroxyl
group, the rigid steroid ring, and the flexible alkyl chain. The 3b-hydroxyl moiety is the only polar group in these sterols thereby contributing to their
amphiphilic character and helps to orient and anchor them in the membrane. (b) The schematic orientation of cholesterol in relation to a phospholipid
molecule in a lipid bilayer. The rigid and near planar steroid ring contributes to the ordering effect of cholesterol in phospholipid bilayers due to the
restriction in motion imposed by it to adjacent phospholipid fatty acyl chains. The flexible alkyl chain extends into the hydrophobic core of the membrane.
Modified from [4].
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aptogenesis require cholesterol [22], the organization and
dynamics of brain cholesterol is still poorly understood
[23]. Brain cholesterol is synthesized in situ [24] and is
developmentally regulated [25]. The organization, traffic,
and dynamics of brain cholesterol are stringently con-
trolled since the input of cholesterol into the central ner-
vous system is almost exclusively from in situ synthesis as
there is no evidence for the transfer of cholesterol from
blood plasma to brain [21]. As a result, a number of neuro-
logical diseases share a common etiology of defective cho-
lesterol metabolism in the brain [26]. The recent increase in
the number of studies in understanding the mechanisms by
which cholesterol metabolism in the brain is regulated
could be attributed to the fact that defects in cholesterol
homeostasis in the brain have been linked to development
of several neurological disorders such as Alzheimer’s
disease, Niemann-Pick type C disease and the Smith–
Lemli–Opitz Syndrome [27]. In the Smith–Lemli–Opitz
Syndrome, for example, the marked abnormalities in brain
development and function leading to serious neurological
and mental dysfunctions have their origin in the fact that
the major input of brain cholesterol comes from the
in situ synthesis and such synthesis is defective in this syn-
drome [28; see later]. In view of the importance of choles-
terol in relation to membrane domains [10,12–16], the
effect of alteration in the cholesterol content of neuronal
membranes on membrane dynamics and protein/receptorfunction represents an important determinant in the analy-
sis of neurogenesis and several neuropathologies. The
interaction between cholesterol and other membrane com-
ponents (such as receptors) in the brain therefore assumes
relevance for a comprehensive understanding of brain
function.
Lipid–protein interactions involving brain cholesterol: the
hippocampal serotonin1A receptor
Lipid–protein interactions play a crucial role in main-
taining the structure and function of biological membranes
[29,30]. A possible role of lipids in a variety of neurological
disorders is well documented. For example, several epide-
miological studies indicate a possible role of lipids in a vari-
ety of neurological disorders which have been shown to
involve deregulated lipid metabolism [1,26]. Since most of
the functions of the membrane are mediated by membrane
proteins, monitoring lipid–protein interactions assumes
significance. A large portion of any given transmembrane
protein remains in contact with the membrane lipid envi-
ronment. This raises the obvious possibility that the mem-
brane could be an important modulator of protein
structure and function. Lipid–protein interactions are
implicated in the assembly, stability and function of mem-
brane proteins [29,30]. Such lipid–protein interactions are
of particular importance because a cell has the ability of
varying the lipid composition of its membrane in response
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ronment and the activity of the receptors in its membrane.
In this context, cholesterol is an important membrane lipid
since it has been implicated in the formation and stability
of membrane domains [10,12–16], the interaction of choles-
terol with membrane proteins [4,31] represents an impor-
tant determinant in functional studies of such proteins,
especially in the nervous system.
Seven transmembrane domain G-protein coupled recep-
tors (GPCRs) constitute one of the largest family of pro-
teins in mammals and account for 2% of the total
proteins coded by the human genome [32]. Signal transduc-
tion events mediated by GPCRs are the primary means by
which cells communicate with and respond to their external
environment [33]. These receptors can be activated by
ligands as chemically diverse as biogenic amines, peptides,
glycoproteins, lipids, nucleotides, and even photons, there-
by mediating diverse physiological processes such as
neurotransmission, cellular metabolism, secretion, cellular
differentiation, and growth, and inflammatory, and im-
mune responses. As a consequence, GPCRs represent
major targets for the development of novel drug candidates
in all clinical areas [34]. It is estimated that up to 50% of
clinically prescribed drugs act as either agonists or antago-
nists for GPCRs, which points out their immense therapeu-
tic potential [35]. Since a large number of GPCRs are
present in the nervous system and are responsible for neu-
ronal function, the interaction of these transmembrane
proteins with the surrounding lipid environment assumes
significance in understanding their function.
The serotonin1A (also referred to as 5-HT1A) receptor is
an important neurotransmitter receptor and is a represen-
tative member of the large family of GPCRs. It is the most
extensively studied of the serotonin receptors for a number
of reasons [36]. Serotonergic signaling plays a key role in
the generation and modulation of various cognitive and
behavioral functions. Interestingly, mutant (knockout)
mice lacking the serotonin1A receptor generated a few years
back exhibit enhanced anxiety-related behavior, and repre-
sent an important animal model for the analysis of complex
traits such as anxiety disorders and aggression in higher
animals [37,38]. In addition, the serotonin1A receptor has
recently been shown to have a role in neural development
[39] and protection of stressed neuronal cells undergoing
degeneration and apoptosis [40]. The modulatory role of
cholesterol on the ligand binding activity and G-protein
coupling of the hippocampal serotonin1A receptor has
recently been shown by depleting cholesterol from native
membranes using methyl-b-cyclodextrin (MbCD), which
selectively extracts cholesterol from membranes by includ-
ing it in a central non-polar cavity. Removal of cholesterol
from hippocampal membranes using various concentra-
tions of MbCD [see Fig. 2a, 41] resulted in a concentra-
tion-dependent reduction in specific binding of the
agonist 8-OH-DPAT to serotonin1A receptors (Fig. 2b).
This is accompanied by alterations in binding sites
obtained from analysis of binding data. Importantly,cholesterol depletion affected G-protein coupling of the
receptor. Replenishment of membranes with cholesterol
using MbCD-cholesterol complex (Fig. 2c), led to recovery
of ligand binding activity (Fig. 2d) to a considerable extent.
If cholesterol is necessary for ligand binding of the seroto-
nin1A receptor, modulating cholesterol availability by other
means could lead to similar effects on the serotonin1A
receptor function. This hypothesis was validated by treat-
ment of native hippocampal membranes with the (i) ste-
rol-complexing agent digitonin [42], (ii) sterol-binding
antifungal polyene antibiotic nystatin [43], and (iii) choles-
terol oxidase which catalyses the oxidation of cholesterol to
cholestenone [44]. While treatment with MbCD physically
depletes cholesterol from membranes, treatment with these
agents modulates the availability of membrane cholesterol
without physical depletion. The common finding in all
these experiments was reduction in the specific agonist
binding, implicating that it is the non-availability of choles-
terol rather than the manner in which its availability is
modulated, is crucial for ligand binding. Taken together,
these results provide evidence that cholesterol is necessary
for ligand binding and G-protein coupling of this impor-
tant neurotransmitter receptor. More importantly, these
results could have significant implications in understanding
the influence of the membrane lipid environment on the
activity and signal transduction of other G-protein coupled
transmembrane receptors. The requirement of membrane
cholesterol in the function of a related receptor, the seroto-
nin7(a) receptor, has recently been reported [45]. Interest-
ingly, the clinical significance of membrane cholesterol
levels resulting in receptor dysfunction has previously been
aptly exemplified in the case of cholecystokinin (CCK)
receptors [46,47]. Thus, agonist binding and G-protein cou-
pling are reduced in case of CCK receptors isolated from
muscle tissues of human gallbladders with cholesterol
stones. These effects were found to be reversed upon treat-
ment with cholesterol-free liposomes.
The most important aspect of the above results is that
manipulations of membrane cholesterol content can
induce significant changes in the activity and G-protein
coupling of the serotonin1A receptor. Whether such
manipulations in membrane cholesterol content could be
induced in vivo represents a challenging question. Low
serum cholesterol concentration has previously been corre-
lated with an increase in the prevalence of suicide in
humans [48] and is partly attributed to an altered seroto-
nin metabolism [49]. The above results on the effect of a
reduction in membrane cholesterol levels on the function
of the serotonin1A receptor could therefore provide poten-
tial insight behind the etiology of psychiatric disorders
that are correlated with altered cholesterol metabolism.
Interestingly, a previous report has suggested that chronic
in vivo administration of certain statins, which are choles-
terol lowering drugs, specifically reduce brain cholesterol
levels leaving the serum cholesterol levels unaffected [50].
Importantly, it has recently been shown that even modest
levels of cholesterol reduction achieved using statins can
Fig. 2. Cholesterol is required for the specific binding of the agonist [3H]8-OH-DPAT to hippocampal serotonin1A receptors. (a) The effect of increasing
concentrations of methyl-b-cyclodextrin (MbCD) on the percentage of cholesterol content of native hippocampal membranes. Increasing concentrations
of MbCD leads to a progressive reduction in the cholesterol content. (b) The specific [3H]8-OH-DPAT binding is reduced upon treatment of native
hippocampal membranes with increasing concentrations of MbCD. This indicates loss in specific agonist binding of serotonin1A receptors upon reduction
in membrane cholesterol levels. Values are expressed as a percentage of specific binding for native membranes without MbCD treatment. (c) Cholesterol
replenishment into hippocampal membranes treated with MbCD. The final cholesterol contents (expressed as a percentage of cholesterol content in native
membrane without any treatment) when cholesterol-depleted membranes were treated with cholesterol-MbCD complex at a final concentration of 0.5:5
and 1:10 mM (mol/mol of cholesterol:MbCD) are shown. (d) Cholesterol replenishment into hippocampal membranes treated with MbCD and its
correlation with specific [3H]8-OH-DPAT binding activity of the hippocampal serotonin1A receptor. Cholesterol depletion resulted in 50% reduction in
specific [3H]8-OH-DPAT binding (see b). Upon replenishment of membrane cholesterol in cholesterol-depleted hippocampal membranes using cholesterol-
MbCD complex, a significant recovery in the specific [3H]8-OH-DPAT binding is observed. Values are expressed as a percentage of specific radiolabeled
agonist binding in native membranes without any treatment. Adapted and modified from [41].
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nin1A receptor (T.J. Pucadyil, S. Shrivastava and A.
Chattopadhyay, unpublished observations). In addition,
a recent report describes the attenuation of the seroto-
nin1A receptor antagonist binding and signaling in brains
of suicide victims [51].
Previous clinical studies have identified abnormalities in
serum cholesterol levels in patients with mood and anxiety
disorders [5]. The corresponding changes in brain choles-
terol levels, if any, would be an important determinant in
characterizing the extent of these disorders [52]. Important-
ly, it has been shown that treating humans with cholesterol
lowering drugs significantly decreases the incidence of Alz-
heimer’s disease [53,54]. It is possible that more severe defi-
ciency in cholesterol levels in the brain occurs on account
of the lower turnover of cholesterol in this tissue. The turn-
over of brain cholesterol is very low, with a half-life of 6months [21]. As a result, the cerebrospinal fluid levels of
cholesterol are 40 to 50-fold lower than the plasma cho-
lesterol [55]. Due to the presence of the blood–brain barri-
er, alterations in serum levels of cholesterol are believed not
to affect the total cholesterol level in the central nervous
system. However, under such conditions, the neuronal
plasma membrane fractions have not been studied ade-
quately. In addition, regions in the central nervous system
(such as the hypothalamic area) that are somewhat weakly
protected by the blood–brain barrier may be sensitive to
plasma cholesterol fluctuations. Interestingly, there are
conditions (such as in the case of the Smith–Lemli–Opitz
Syndrome, see later) in which brain cholesterol availability
is limited due to defective cholesterol biosynthesis.
Whether the function of membrane receptors such as the
serotonin1A receptor gets modulated under such condition
represents an intriguing question.
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cholesterol biosynthesis: the Smith–Lemli–Opitz Syndrome
The Smith–Lemli–Opitz Syndrome [56] is an autosomal
recessive disorder characterized clinically by mental retar-
dation, physical deformities, failure to thrive, and multiple
congenital anomalies. SLOS is caused by mutations in 7-
dehydrocholesterol reductase, an enzyme required in the
penultimate step of cholesterol biosynthesis [see Fig. 3;
57]. The principal route of cholesterol biosynthesis in
humans is the Kandutsch-Russell pathway [58]. In this
pathway, the immediate precursor of cholesterol is 7-dehy-
drocholesterol (7-DHC) which differs with cholesterol in its
unsaturation at 7th position (between the 7th and 8th car-
bons) in the sterol ring (highlighted in Fig. 3). SLOS is the
second most serious recessive genetic condition after cystic
fibrosis. Elevated plasma levels of 7- and 8-dehydrocholes-
terol and the ratio of their concentration to that of choles-
terol are representative parameters for diagnosis of SLOS.
The brains of individuals with SLOS are characterized by
partial to complete agenesis of the cerebellar vermis and/
or corpus callosum, hypoplasia of frontal lobes, and occa-
sionally holoprosencephaly [28,59]. Since SLOS is associat-
ed with neurological deformities and malfunction,
exploring the function of neuronal receptors and their
membrane lipid interactions under these conditions could
be relevant. Because cholesterol is often found to be non-
randomly distributed in domains in membranes, which
are physiologically important for membrane function
[13,14], the putative localization of 7-DHC in such
domains assumes significance. Interestingly, it has recently
been reported that 7-DHC forms more stabilized domains
in model membranes compared to cholesterol [60]. In addi-OH OH
Lanosterol 7-Dehydrocho
Acetate
HMG-CoA
Mevalonate
HMG-CoA reductase
Fig. 3. A schematic representation showing the pathogenesis of the Smith–
biosynthesis. The principal route of cholesterol synthesis in humans is the Kan
cholesterol is 7-dehydrocholesterol (7-DHC) which differs in its unsaturation a
reduction of 7-DHC to yield cholesterol is catalyzed by 3b-hydroxysterol D
developmental disorder associated with multiple congenital and morphogenic an
parameter of the Smith–Lemli–Opitz Syndrome (see text for more details).tion, 7-DHC incorporated in model membranes has recent-
ly been shown to result in reduced bending rigidity and
intrinsic curvature compared to cholesterol [61]. Using skin
fibroblasts from SLOS patients, Tulenko and co-workers
have recently shown that SLOS is accompanied by general
membrane defects [62]. Taken together, these results point
out that SLOS could have potential implications in mem-
brane organization and dynamics, and ultimately in the
function of membrane proteins due to altered interaction
with cholesterol.
Conclusion and future perspectives
In this review, we have highlighted lipid–protein interac-
tions involving brain cholesterol taking the specific exam-
ple of the hippocampal serotonin1A receptor, an
important transmembrane neurotransmitter receptor,
which belongs to the family of GPCRs. These results
assume significance in light of the fact that serotonin1A
receptor function is greatly modulated, possibly due to
the altered membrane lipid environment surrounding this
protein, in case of many psychiatric disorders. For exam-
ple, the serotonin1A receptor levels and function have been
shown to be important indices to diagnose several psychi-
atric disorders such as schizophrenia, major depression
and suicide in humans [63–65].
In spite of a number of clinical reports, the link between
psychiatric disorders due to altered cholesterol levels
[26,27] and the interaction of cholesterol with membrane
proteins and receptors (the key components in neural sig-
nal transduction) in healthy and diseased conditions, in
molecular details is lacking. The diversity of lipids found
in natural membranes, combined with the ability of cellsOH
lesterol Cholesterol
Defective step in SLOS
7-Δ-Reductase(DHCR7)
Lemli–Opitz Syndrome (SLOS) due to metabolic defect in cholesterol
dutsch–Russell pathway [58]. In this pathway, the immediate precursor of
t 7th position in the sterol ring (highlighted in its chemical structure). The
7-reductase (7-DHCR). Mutations in this enzyme cause SLOS, a severe
omalies. Elevated levels of 7-DHC have been characterized as a diagnostic
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states, vastly increase the potential by which lipids can
exert their influence on membrane receptor and protein
function, thereby leading to various psychiatric disorders.
The development of newer and more sensitive technologies
capable of monitoring receptor interactions at the mem-
brane level would lead to a better understanding of the
pathogenesis of these diseases.Acknowledgments
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